Nuvation Bio Inc. (NUVB): who owns it and who trades it
As of Nov 16, 2026, NUVB insiders reported 16 open-market sales worth $9.2M and 1 purchase worth $118K in the last 12 months, with 38% of the sale value made under pre-set 10b5-1 plans. The largest seller was Gary Hattersley (CHIEF SCIENTIFIC OFFICER), with $3.4M. 6 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Nuvation Bio
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns NUVB
243 funds and institutions reported NUVB shares worth $1.3B at the end of Q2 2026, about 68% of the company. The largest holder is FMR LLC (Fidelity) with 15.0%.
Funds and institutions (13F) 68%Everyone else 32%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| FMR LLC (Fidelity) | 52.23M | 15.00% | $297M | +0% |
| BlackRock, Inc. | 27.63M | 7.94% | $157M | +10% |
| Decheng Capital LLC | 25.95M | 7.45% | $147M | No change |
| Vanguard Capital Management LLC | 11.92M | 3.42% | $67.7M | +3% |
| Omega Fund Management, LLC | 8.08M | 2.32% | $45.9M | No change |
| Laurion Capital Management LP | 7.82M | 2.25% | $44.4M | No change |
| State Street Corp | 7.37M | 2.12% | $41.9M | +9% |
| Geode Capital Management, LLC | 6.24M | 1.79% | $35.5M | +7% |
| Duquesne Family Office LLC | 4.54M | 1.30% | $25.8M | No change |
| American Century Companies Inc | 4.50M | 1.29% | $25.6M | +55% |
| Bank of America Corp | 3.53M | 1.01% | $20M | +10% |
| Tang Capital Management LLC | 3.30M | 0.95% | $18.7M | +5% |
| Redmile Group, LLC | 3.03M | 0.87% | $17.2M | -4% |
| Vanguard Portfolio Management LLC | 2.69M | 0.77% | $15.3M | +18% |
| AQR Capital Management LLC | 2.36M | 0.68% | $13.4M | +18% |
| Northern Trust Corp | 2.32M | 0.67% | $13.2M | +16% |
| Algert Global LLC | 2.28M | 0.65% | $12.9M | +24% |
| Hrt Financial LP | 2.21M | 0.63% | $12.5M | – |
| Charles Schwab Investment Management Inc | 2.06M | 0.59% | $11.7M | +3% |
| Sixth Street Partners Management Company, L.P. | 2.06M | 0.59% | $11.7M | – |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, NUVB insiders reported $118K of open-market purchases and $9.2M of sales. 38% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Aug 19, 2026 | Gary Hattersley | CHIEF SCIENTIFIC OFFICER | Sale plan | 100,000 | $7.09 | $709K | Form 4 |
| Jun 23, 2026 | Stacy Markel | CHIEF PEOPLE OFFICER | Sale plan | 125,000 | $6.03 | $754K | Form 4 |
| Jun 23, 2026 | Kerry Wentworth | CHIEF REGULATORY OFFICER | Sale plan | 63,000 | $6.02 | $379K | Form 4 |
| Jun 23, 2026 | Philippe Sauvage | CFO | Sale plan | 47,668 | $6.01 | $286K | Form 4 |
| Jun 9, 2026 | Robert Mashal | Director | Purchase | 25,000 | $4.73 | $118K | Form 4 |
| Apr 17, 2026 | Kerry Wentworth | CHIEF REGULATORY OFFICER | Sale plan | 36,750 | $5.01 | $184K | Form 4 |
| Apr 17, 2026 | Dongfang Liu | CHIEF MEDICAL OFFICER | Sale plan | 50,000 | $5.02 | $251K | Form 4 |
| Apr 6, 2026 | Kerry Wentworth | CHIEF REGULATORY OFFICER | Sale plan | 200,000 | $4.52 | $904K | Form 4 |
| Dec 1, 2025 | Dongfang Liu | CHIEF MEDICAL OFFICER | Sale | 150,000 | $7.82 | $1.2M | Form 4 |
| Nov 26, 2025 | Dongfang Liu | CHIEF MEDICAL OFFICER | Sale | 10,000 | $8.00 | $80K | Form 4 |
| Nov 25, 2025 | Dongfang Liu | CHIEF MEDICAL OFFICER | Sale | 10,000 | $7.50 | $75K | Form 4 |
| Nov 20, 2025 | Gary Hattersley | CHIEF SCIENTIFIC OFFICER | Sale | 69,051 | $7.23 | $499K | Form 4 |
| Nov 20, 2025 | Gary Hattersley | CHIEF SCIENTIFIC OFFICER | Sale | 300,000 | $7.23 | $2.2M | Form 4 |
| Nov 20, 2025 | Dongfang Liu | CHIEF MEDICAL OFFICER | Sale | 20,000 | $7.00 | $140K | Form 4 |
| Nov 19, 2025 | David C. Hanley | CHIEF TECHNICAL OPERATIO | Sale | 200,000 | $7.14 | $1.4M | Form 4 |
| Nov 19, 2025 | Dongfang Liu | CHIEF MEDICAL OFFICER | Sale | 15,000 | $5.10 | $76.5K | Form 4 |
| Nov 17, 2025 | Dongfang Liu | CHIEF MEDICAL OFFICER | Sale | 15,000 | $4.77 | $71.5K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Gary Hattersley | CHIEF SCIENTIFIC OFFICER | – | $3.4M | Aug 19, 2026 |
| Dongfang Liu | CHIEF MEDICAL OFFICER | – | $1.9M | Apr 17, 2026 |
| Kerry Wentworth | CHIEF REGULATORY OFFICER | – | $1.5M | Jun 23, 2026 |
| David C. Hanley | CHIEF TECHNICAL OPERATIONS | – | $1.4M | Nov 19, 2025 |
| Stacy Markel | CHIEF PEOPLE OFFICER | – | $754K | Jun 23, 2026 |
| Philippe Sauvage | Chief Financial Officer | – | $286K | Jun 23, 2026 |
| Robert Mashal | Director | $118K | – | Jun 9, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
NUVB short interest
High short interest. 17.6% of NUVB shares are sold short: about 1 share in 6. Over the last 12 reports the number of shares short went up 20%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 62.00M NUVB shares were sold short, 17.6% of the shares outstanding, down 1.9% from the report before. At the average daily volume of 4.96M shares, buying them all back would take about 12.5 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 62.00M | 17.56% | -2% | 4.96M | 12.5 |
| Oct 15, 2026 | 63.22M | 18.01% | +7% | 6.55M | 9.7 |
| Sep 30, 2026 | 58.86M | 16.76% | +1% | 4.24M | 13.9 |
| Sep 15, 2026 | 58.17M | 16.57% | +7% | 5.34M | 10.9 |
| Aug 31, 2026 | 54.26M | 15.45% | +2% | 5.09M | 10.7 |
| Aug 14, 2026 | 53.22M | 15.16% | -0% | 6.00M | 8.9 |
| Jul 31, 2026 | 53.42M | 15.34% | -4% | 6.14M | 8.7 |
| Jul 15, 2026 | 55.67M | 15.99% | +2% | 6.93M | 8.0 |
| Jun 30, 2026 | 54.36M | 15.61% | +11% | 11.72M | 4.6 |
| Jun 15, 2026 | 48.92M | 14.05% | -9% | 5.08M | 9.6 |
| May 29, 2026 | 53.67M | 15.41% | +4% | 3.74M | 14.3 |
| May 15, 2026 | 51.49M | 14.79% | +2% | 5.17M | 10.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Nuvation Bio company events
Nuvation Bio filed 10 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 4, 2026.
- Nov 4, 2026ResultsReleased financial results. Filing
- Aug 6, 2026ResultsReleased financial results. Filing
- Jul 6, 2026AnnouncementThe Company issued a press release announcing the issuance of the additional Notes pursuant to the Greenshoe Exercise and the entry into the additional capped call confirmations. Filing
- Jun 30, 2026AgreementNuvation Bio Inc. completed its registered underwritten public offering of $250.0 million of 0.75% Convertible Senior Notes due 2032, pursuant to the Underwriting Agreement, dated June 25, 2026 with Jefferies LLC, Citigroup Global Markets Inc., and Cantor Fitzgerald & Co. as representatives of the… Filing
- May 27, 2026VoteReported shareholder vote results. Filing
- May 4, 2026ResultsReleased financial results. Filing
- Mar 2, 2026ResultsReleased financial results. Filing
- Jan 12, 2026AgreementNuvation Bio Inc. entered into a License and Collaboration Agreement with Eisai Co., Ltd. Filing
- Nov 26, 2025AnnouncementThe Company announced its decision to discontinue development of NUV-1511, the first compound in its first-of-its-kind drug-drug conjugate (DDC) program. Filing
- Nov 17, 2025AnnouncementPositive results from a Phase 2 study of safusidenib in Japanese patients with chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutant gliomas were published in the online journal of Neuro-Oncology. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Nuvation Bio financials
Famous investors that hold NUVB
6 of the 50 well-known investors we track reported holding NUVB in their latest 13F filing. The largest position is Ken Griffin's, worth $13.3M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 2.37M | $13.3M | 0.0% | +19% |
| Stanley Druckenmiller · Duquesne Family Office | Q3 2026 | 2.27M | $12.7M | 0.3% | -50% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 1.32M | $7.4M | 0.0% | -2% |
| Israel Englander · Millennium Management | Q3 2026 | 700,196 | $3.9M | 0.0% | +88% |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 267,032 | $1.5M | 0.0% | New |
| David Einhorn · Greenlight Capital (DME) | Q3 2026 | 34,995 | $196K | 0.0% | No change |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about Nuvation Bio Inc. (NUVB) stock
Who owns the most NUVB stock?
The largest reported owner of Nuvation Bio Inc. (NUVB) is FMR LLC (Fidelity), with 15.0% of the company. In total, 243 funds and institutions reported holding NUVB at the end of Q2 2026, together about 68% of the shares. See the largest owners.
Are NUVB insiders buying or selling?
In the last 12 months, NUVB insiders reported 1 open-market purchase worth $118K and 16 sales worth $9.2M. The latest trade was on Aug 19, 2026. See every trade.
What is the short interest in NUVB?
As of Oct 30, 2026, 62.00M NUVB shares were sold short, 17.6% of the shares outstanding, down 1.9% from the report before. At the average daily volume of 4.96M shares, buying them all back would take about 12.5 trading days (days to cover). See the history.
Which famous investors hold NUVB?
6 of the 50 well-known investors we track reported NUVB in their latest 13F filing, including Ken Griffin, Stanley Druckenmiller, Jim Simons. The largest position is worth $13.3M. See all holders.
Executive pay
Nuvation Bio's chief executive was paid a total of $3.9M for the year ended Dec 31, 2025, up 4% from $3.7M the year before. In the last 12 months, Nuvation Bio's executives and directors bought $118K of stock on the open market and sold $9.2M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.